基于复杂网络的中医方剂治疗肺癌核心药物及其干预靶点分析

A Preliminary Study on the Core Drugs and Intervention Targets of Traditional Chinese Medicine Prescription for Lung Cancer Based on Complex Network

目的探讨中药方剂治疗肺癌的核心药物以及对其作用机制和效应靶点预测。方法通过复杂网络的方法基于近20年文献首先筛选中药方剂中治疗肺癌的主药,再通过中药网络药理学数据库以及TCGA肿瘤全基因组数据库,通过数据挖掘方法探讨预测主药治疗肺癌的机制及关键靶点,并通过大数据高通量全基因组信息观察调节关键靶点对肺癌患者生存期的影响。结果黄芪是肺癌治疗中医方药中的核心主药,不仅使用率最高并且与其他药物的配伍最多,能有效干预磷脂酶D1(phospholipaseD1,PLD1)基因靶点,而PLD1作为特异性基因在肺癌尤其是小细胞肺癌中呈现高表达,调节PLD1的表达可有效提高小细胞肺癌患者的生存率。结论黄芪是肺癌治疗方药中的核心主药,其机制可能是干预PLD1起作用。

Objective To explore the core herbs of traditional Chinese medicine prescriptions in the treatment of lung cancer and to predict their action mechanism and effect targets.Methods Based on the literature of the past twenty years,we first screened the main drugs for lung cancer in Chinese herbal prescriptions,and then explored the mechanism and key targets of the main drugs for lung cancer treatment by data mining through Chinese herbal network pharmacology database and TCGA tumor genome database,and then observed and adjusted the key points by large data and high throughput genome-wide information.Results Astragalus membranaceus is the core of Chinese medicine in the treatment of lung cancer,not only with the highest utilization rate but also with the most compatibility with other drugs,it can effectively interfere with PLD1 gene target,and PLD1 as a specific gene in lung cancer,especially in small cell lung cancer shows high expression,regulating PLD1.Conclusion Astragalus membranaceus is the core drug in the treatment of lung cancer,and its effective mechanism may be through the intervention of PLD1.